A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood

AR Lourenço, PJ Coffer - Oncogene, 2017 - nature.com
The transcription factor CCAAT/enhancer-binding protein alpha (C/EBPα) plays a critical
role during embryogenesis and is thereafter required for homeostatic glucose metabolism …

Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human …

R Liu, Y Li, L Tian, H Shi, J Wang, Y Liang, B Sun… - Cancer Letters, 2019 - Elsevier
Gankyrin plays important roles in tumorigenicity and metastasis of hepatocellular carcinoma
(HCC). We have for the first time investigated the effects of Gankyrin on glycolysis and …

[HTML][HTML] Gankyrin as a potential target for tumor therapy: evidence and perspectives

H Li, J Zhang, C Zhen, B Yang… - American journal of …, 2018 - ncbi.nlm.nih.gov
Gankyrin (also known as PSMD10 or p28GANK), engages in diverse biological processes,
including cellular growth, proliferation and invasion. Several studies have demonstrated that …

Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells

M Lei, YL Zhang, FY Huang, HY Chen, MH Chen… - Scientific Reports, 2023 - nature.com
Gankyrin is found in high levels in triple-negative breast cancer (TNBC) and has been
established to form a complex with the E3 ubiquitin ligase MDM2 and p53, resulting in the …

LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway

X Song, J Wang, T Zheng, R Song, Y Liang, N Bhatta… - Molecular cancer, 2013 - Springer
Background Gankyrin has shown to be overexpressed in human liver cancers and plays a
complex role in hepatocarcinogenesis. Panobinostat (LBH589), a new hydroxamic acid …

Small-molecule Gankyrin inhibition as a therapeutic strategy for breast and lung cancer

D Kanabar, M Goyal, EI Kane, T Chavan… - Journal of medicinal …, 2022 - ACS Publications
Gankyrin is an oncoprotein responsible for the development of numerous cancer types. It
regulates the expression levels of multiple tumor suppressor proteins (TSPs) in liver cancer; …

[HTML][HTML] MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression

J Li, F Tian, D Li, J Chen, P Jiang, S Zheng, X Li… - FEBS letters, 2014 - Elsevier
The aberrant expression of PSMD10 has important functions in various malignancies. This
study showed that PSMD10 was highly expressed and inversely correlated with the …

[HTML][HTML] PSMB4 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis

H Wang, Z He, L Xia, W Zhang, L Xu… - Oncology …, 2018 - spandidos-publications.com
Abstract PSMB4, proteasome subunit β4, is a member of the ubiquitin-proteasome family,
and is elevated in a variety of malignancies. However, the expression level and related …

Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma

P Zamani, M Matbou Riahi… - Artificial Cells …, 2018 - Taylor & Francis
Hepatocellular carcinoma (HCC) is known as fifth common malignancies and third common
cause of cancer-related death worldwide. The identification of various mechanisms which …

Gankyrin promotes epithelial-mesenchymal transition and metastasis in NSCLC through forming a closed circle with IL-6/STAT3 and TGF-β/SMAD3 signaling pathway

W Wang, Y Sun, Q Lu, J Zhao, X Wang, Z Chen… - …, 2016 - pmc.ncbi.nlm.nih.gov
Our previous research showed that Gankyrin was overexpressed in NSCLC and significantly
associated with clinicopathologic features and poor prognosis. In this study, we will explore …